{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.8","upperLimit":"51.0","value":"39.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"}],"units":"Participants"}],"description":"Participants who were eligible for allogeneic HSCT were those who achieved remission (complete response or complete response with partial recovery of peripheral blood counts) after 2 cycles of blinatumomab treatment, and no further anti-leukemic medication was given before HSCT.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"NUMBER","populationDescription":"Participants who reached complete remission or complete remission with partial hematological recovery during the first 2 cycles of treatment.","reportingStatus":"POSTED","timeFrame":"Up to the data cut-off date of 10 October 2013. Maximum duration on study was 17.8 months.","title":"Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission","type":"SECONDARY","unitOfMeasure":"percentage of participants"}